Fig. 2From: Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspectiveTornado diagrams of sensitivity analyses of BORT vs DEX and LEN/DEX vs BORTBack to article page